Tandem Diabetes Care (NASDAQ:TNDM) Upgraded to Strong-Buy at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a buy rating to a strong-buy rating in a research report report published on Thursday, BidAskClub reports.

A number of other equities analysts have also issued reports on TNDM. Cowen increased their target price on shares of Tandem Diabetes Care from $70.00 to $85.00 and gave the company an outperform rating in a research report on Thursday, February 13th. Robert W. Baird lowered shares of Tandem Diabetes Care from an outperform rating to a neutral rating and increased their target price for the company from $71.00 to $75.00 in a research report on Tuesday, February 4th. ValuEngine upgraded shares of Tandem Diabetes Care from a sell rating to a hold rating in a research report on Tuesday, February 4th. Craig Hallum reiterated a buy rating and issued a $92.00 target price on shares of Tandem Diabetes Care in a research report on Wednesday, February 12th. Finally, Raymond James assumed coverage on shares of Tandem Diabetes Care in a research report on Wednesday, February 5th. They issued an outperform rating and a $85.00 target price for the company. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $79.79.

TNDM traded down $1.94 on Thursday, reaching $88.00. The company had a trading volume of 1,351,280 shares, compared to its average volume of 1,566,407. The company has a fifty day moving average of $73.17 and a 200-day moving average of $65.33. The company has a market capitalization of $5.32 billion, a P/E ratio of -176.00 and a beta of 0.08. The company has a current ratio of 2.46, a quick ratio of 2.05 and a debt-to-equity ratio of 0.09. Tandem Diabetes Care has a one year low of $47.36 and a one year high of $91.65.

In other news, EVP David B. Berger sold 8,000 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $67.83, for a total transaction of $542,640.00. Following the completion of the transaction, the executive vice president now owns 11,311 shares in the company, valued at approximately $767,225.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John F. Sheridan sold 462 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $70.00, for a total transaction of $32,340.00. Following the transaction, the chief executive officer now owns 2,963 shares of the company’s stock, valued at approximately $207,410. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 309,778 shares of company stock valued at $20,217,001. Insiders own 6.90% of the company’s stock.

Several large investors have recently bought and sold shares of TNDM. FMR LLC boosted its holdings in shares of Tandem Diabetes Care by 175.9% in the fourth quarter. FMR LLC now owns 2,345,167 shares of the medical device company’s stock worth $139,796,000 after buying an additional 1,495,259 shares during the period. Delphi Management Partners VIII L.L.C. acquired a new position in shares of Tandem Diabetes Care in the fourth quarter worth about $59,610,000. Jennison Associates LLC acquired a new position in shares of Tandem Diabetes Care in the fourth quarter worth about $30,080,000. Perceptive Advisors LLC boosted its holdings in shares of Tandem Diabetes Care by 4,727.2% in the fourth quarter. Perceptive Advisors LLC now owns 310,000 shares of the medical device company’s stock worth $18,479,000 after buying an additional 303,578 shares during the period. Finally, Great Point Partners LLC acquired a new position in shares of Tandem Diabetes Care in the third quarter worth about $14,745,000. Institutional investors own 88.79% of the company’s stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: What is the Consumer Price Index (CPI)?

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.